The trademark application LYNOZYFIC was filed by Regeneron Pharmaceuticals, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on March 21, 2023, and it was registered by office on June 28, 2023 without any oppositions.
The application was filed in English (German was selected as the second language).
Goods And Services
The mark was filed in class 5 with Pharmaceutical preparations for the treatment of hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral diseases and disorders, and for the treatment of pain.